We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About BRIM Biotechnology Stock

Invest in or calculate the value of your shares in BRIM Biotechnology or other pre-IPO companies through EquityZen's platform.

Get Started

BRIM Biotechnology Stock (BRIB)

BRIM Biotechnology is a pharmaceutical company.

About BRIM Biotechnology Stock

Founded

2013

Industries

Software, Artificial Intelligence, Data and Analytics

Founded in 2013, Quanfu Biotechnology Co., Ltd. (hereinafter referred to as Quanfu Biotech) is based in Taiwan and uses the core competitiveness of the translation science field to integrate the virtual team's operating model and is committed to the development of innovative drugs.   The professional team of Quanfu Biotech has screened the innovation sources of domestic and foreign companies with rich experience in new drug development, including: academic research, small biotechnology companies, and international pharmaceutical companies, for joint research and development, technology introduction, etc. In a way that closely combines the energy of both parties to develop drug development, and then introduces the most suitable CRO and CMO strategic partners to promote innovative drugs to the “proof of concept” (POC) stage, followed by authorization and partnering. In this way, the research and development of innovative drugs will be handed over to the most potential development team, and the late clinical trials of drug research and development will be carried out to push the products to the market.

BRIM Biotechnology Management

Leadership team at BRIM Biotechnology

Founder and CEO

Haishan Jang

Chairman and general manager

Dr. Jian Haishan

Locked Features

Join now and verify your accreditation status to gain access to:

  • BRIM Biotechnology current valuation
  • BRIM Biotechnology stock price
  • Available deals in BRIM Biotechnology and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

Trading BRIM Biotechnology Stock

How to invest in BRIM Biotechnology stock?

Accredited investors can buy pre-IPO stock in companies like BRIM Biotechnology through EquityZen funds. These investments are made available by existing BRIM Biotechnology shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell BRIM Biotechnology stock?

Shareholders can sell their BRIM Biotechnology stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."